(RTTNews) - Deciphera Pharmaceuticals, Inc. (DCPH) Monday announced positive top-line results from the pivotal Phase 3 MOTION study of its investigational drug Vimseltinib in patients with ...
Health Canada’s approval enables 4Moving Biotech to initiate the INFLAM MOTION Phase 2a clinical trial The INFLAM MOTION trial serves as a proof-of-concept study for 4Moving Biotech’s flagship 4P004 ...
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results